We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 03, 2021

CD47 Blocker in Patients With Relapsed or Refractory Hematologic Malignancies

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Phase 1 Study of the CD47 Blocker TTI-621 in Patients With Relapsed or Refractory Hematologic Malignancies
Clin. Cancer Res 2021 Jan 15;[EPub Ahead of Print], SM Ansell, M Maris, AM Lesokhin, R Chen, IW Flinn, A Sawas, MD Minden, D Villa, MM Percival, AS Advani, JM Foran, S Horwitz, M Mei, J Zain, KJ Savage, C Querfeld, OE Akilov, LD Johnson, T Catalano, PS Petrova, RA Uger, EL Sievers, A Milea, K Roberge, Y Shou, OA O'Connor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading